Literature DB >> 16041839

Chromatin modifications as targets for new anticancer drugs.

Stefan Schäfer1, Manfred Jung.   

Abstract

Chromatin proteins undergo diverse posttranslational modifications, esp. acetylation and methylation, that contribute to the control of transcriptional processes. The result of these modifications in its various states is called the histone code. This review presents an overview of those modifications of chromatin proteins that affect the side chains of lysines and arginines and define variations of the chromatin acetylome and methylome. The relevant enzymes are presented and the feasibility to influence their activity by inhibition or activation is discussed. The manipulation of these enzymes is an exciting strategy towards an increased understanding of their role in the functionality of a cell. Additionally, this may lead to new approaches for the treatment of diseases that are based on a dysregulation of transcription, especially cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041839     DOI: 10.1002/ardp.200500984

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  7 in total

1.  Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of Competitors.

Authors:  Sascha Venturelli; Regina G Belz; Andreas Kämper; Alexander Berger; Kyra von Horn; André Wegner; Alexander Böcker; Gérald Zabulon; Tobias Langenecker; Oliver Kohlbacher; Fredy Barneche; Detlef Weigel; Ulrich M Lauer; Michael Bitzer; Claude Becker
Journal:  Plant Cell       Date:  2015-11-03       Impact factor: 11.277

2.  Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.

Authors:  L Marquard; L M Gjerdrum; Ib J Christensen; P B Jensen; M Sehested; E Ralfkiaer
Journal:  Histopathology       Date:  2008-09       Impact factor: 5.087

3.  Histones: Controlling Tumor Signaling Circuitry.

Authors:  Manoela D Martins; Rogerio M Castilho
Journal:  J Carcinog Mutagen       Date:  2013-07-29

4.  Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation.

Authors:  Juxian Wang; Limin Chen; Sarmistha Halder Sinha; Zhongjie Liang; Huifang Chai; Sakthivel Muniyan; Yu-Wei Chou; Chao Yang; Leilei Yan; You Feng; Keqin Kathy Li; Ming-Fong Lin; Hualiang Jiang; Yujun George Zheng; Cheng Luo
Journal:  J Med Chem       Date:  2012-09-12       Impact factor: 7.446

5.  Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.

Authors:  Shaymaa E Kassab; Samar Mowafy; Aya M Alserw; Joustin A Seliem; Shahenda M El-Naggar; Nesreen N Omar; Mohamed M Awad
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

6.  Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly.

Authors:  Takayoshi Suzuki; Yuki Kasuya; Yukihiro Itoh; Yosuke Ota; Peng Zhan; Kaori Asamitsu; Hidehiko Nakagawa; Takashi Okamoto; Naoki Miyata
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

Review 7.  Chromatin as a target for the DNA-binding anticancer drugs.

Authors:  Parijat Majumder; Suman K Pradhan; Pukhrambam Grihanjali Devi; Sudipta Pal; Dipak Dasgupta
Journal:  Subcell Biochem       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.